aflibercept
E238303
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| aflibercept canonical | 2 |
Statements (58)
| Predicate | Object |
|---|---|
| instanceOf |
angiogenesis inhibitor
ⓘ
anti-VEGF agent ⓘ biologic drug ⓘ ophthalmic drug ⓘ recombinant fusion protein ⓘ |
| administrationFrequency |
every 4 weeks (loading phase, intravitreal)
ⓘ
every 8 weeks (maintenance phase, intravitreal) ⓘ |
| coDeveloper |
Bayer
ⓘ
surface form:
Bayer HealthCare
|
| commonAdverseEffect |
cataract
ⓘ
conjunctival hemorrhage ⓘ eye pain ⓘ increased intraocular pressure ⓘ |
| contains |
Fc portion of human IgG1
ⓘ
extracellular domains of VEGFR-1 ⓘ extracellular domains of VEGFR-2 ⓘ |
| contraindication |
active severe intraocular inflammation
ⓘ
ocular or periocular infection ⓘ |
| developer | Regeneron Pharmaceuticals ⓘ |
| hasATCCode |
L01XX44
ⓘ
S01LA05 ⓘ |
| hasTradeName |
Eylea
ⓘ
Zaltrap ⓘ |
| indication |
branch retinal vein occlusion
ⓘ
central retinal vein occlusion ⓘ diabetic macular edema ⓘ macular edema following retinal vein occlusion ⓘ metastatic colorectal cancer ⓘ myopic choroidal neovascularization ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
| legalStatus | prescription only ⓘ |
| mechanismOfAction |
binds VEGF-A
ⓘ
binds VEGF-B ⓘ binds placental growth factor ⓘ inhibits pathological angiogenesis ⓘ prevents VEGF interaction with its receptors ⓘ reduces vascular permeability ⓘ |
| molecularType | fusion protein of VEGF receptor domains and IgG1 Fc ⓘ |
| pregnancyCategory | may cause fetal harm (based on mechanism and animal data) ⓘ |
| regulatoryStatus |
EMA approved
ⓘ
FDA approved ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
intravitreal injection ⓘ |
| seriousAdverseEffect |
endophthalmitis
ⓘ
retinal detachment ⓘ |
| targets |
PlGF
ⓘ
vascular endothelial growth factor A ⓘ
surface form:
VEGF-A
VEGF-B ⓘ placental growth factor ⓘ vascular endothelial growth factor A ⓘ |
| therapeuticArea |
oncology
ⓘ
ophthalmology ⓘ |
| usedWith |
FOLFIRI regimen
ⓘ
fluorouracil ⓘ folinic acid ⓘ irinotecan ⓘ |
| yearOfFirstApproval |
2011 (ophthalmic indication, United States)
ⓘ
2012 (oncology indication, United States) ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.